Zacks.com featured highlights Nutex, RCM, Remitly and Belden

Zacks highlights four stocks—Nutex Health (NUTX), RCM Technologies (RCMT), Remitly (RELY) and Belden (BDC)—as having strong net profit margins and supportive earnings momentum. Estimated 2026 earnings have been revised up for NUTX (+32.5% to $30.11/share), RCMT (+13.3% to $3.07), RELY (+13.8% to $1.57) and BDC (+5.7% to $8.69), while the most recent quarters show broad EPS outperformance (NUTX +82.13%, RCMT +51.85%, RELY +268.97%, BDC +14.71%). The note is portfolio-optimistic but is mainly screening/estimates-driven rather than a fresh catalyst, so likely limited near-term price impact.

Analysis

This screen is more a factor confirmation than a fresh catalyst: positive estimate revisions plus high margins tend to attract momentum and quality buyers, but the edge is usually in the next earnings print, not the article itself. The immediate tradeable effect is likely in small/mid-cap names with thinner liquidity and higher short interest; that argues for tactical exposure, not a blanket long basket.

Among the four, BDC looks like the cleanest fundamental story because industrial connectivity/networking has a real link to capital spending, factory digitization, and AI-related data-center buildout. RELY is the best secular growth asset, but remittance is a pricing war business—competitive pressure from WU and newer fintech rails can offset volume gains if customer acquisition or compliance costs rise. RCMT is more cyclical: utilization and project mix drive margins, so the current estimate uplift is fragile if corporate IT spend or government/engineering budgets soften.

The contrarian risk is that net margin is a noisy screen for microcaps and can overstate durability when one-time items, tax, or SBC move the denominator. NUTX is the most vulnerable to that critique: the estimate revision is large enough to trigger a squeeze, but the quality of those earnings is the key question. I would treat the next 1-3 earnings cycles as the real test; if revisions stop rising or cash conversion disappoints, the rerating should fade quickly. On the other hand, if RELY maintains take-rate and BDC shows margin resilience, the market could keep paying up for quality for 6-18 months.

Key Decisions for Investors

• Long BDC / short XLI for 1-3 months as a quality-vs-beta pair: modest upside if industrial capex stays firm, with a cleaner margin story than the index. Falsify if BDC guidance or gross margin rolls over next quarter.
• Long RELY vs short WU into the next earnings cycle: if digital remittance share gains persist, RELY should compound faster while WU absorbs pricing pressure. Exit if RELY take-rate or customer acquisition economics deteriorate.
• Avoid chasing NUTX on this screen alone; if you want exposure, use a small tactical long only after the next quarter confirms cash earnings, not just EPS revisions. High upside if the revisions are real, but the highest risk of mean reversion.
• RCMT is a watchlist long, not a conviction trade: only buy on a pullback if management reiterates utilization and backlog strength. If project activity softens, this will de-rate quickly because margins are cycle-sensitive.